BibTex format
@article{Liu:2024:ecco-jcc/jjad182,
author = {Liu, Z and Alexander, JL and Eng, KY and Ibraheim, H and Anandabaskaran, S and Saifuddin, A and Constable, L and Seoane, RC and Bewshea, C and Nice, R and D'Mello, A and Jones, GR and Balarajah, S and Fiorentino, F and Sebastian, S and Irving, PM and Hicks, LC and Williams, HRT and Kent, AJ and Linger, R and Parkes, M and Kok, K and Patel, KV and Teare, JP and Altmann, DM and Boyton, RJ and Hart, AL and Lees, CW and Goodhand, JR and Kennedy, NA and Pollock, KM and Ahmad, T and Powell, N and VIP, study investigators},
doi = {ecco-jcc/jjad182},
journal = {Journal of Crohn's and Colitis},
pages = {560--569},
title = {Antibody responses to influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib},
url = {http://dx.doi.org/10.1093/ecco-jcc/jjad182},
volume = {18},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Background and aims:We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with IBD.Methods:We conducted a prospective study including 213 IBD patients and 53 healthy controls; 165 who had received seasonal influenza vaccine and 101 who had not. IBD medications included infliximab, thiopurines, infliximab and thiopurine combination therapy, ustekinumab, vedolizumab or tofacitinib. The primary outcome was antibody responses against influenza/A H3N2 and A/H1N1, compared to controls, adjusting for age, prior vaccination and interval between vaccination and sampling.Results:Lower antibody responses against influenza A/H3N2 were observed in patients on infliximab (Geometric Mean Ratio 0.35 [95% CI 0.20-0.60], p=0.0002), combination of infliximab and thiopurine therapy (0.46 [0.27-0.79], p=0.0050) and tofacitinib (0.28 [0.14-0.57], p=0.0005) compared to controls. Lower antibody responses against A/H1N1 were observed in patients on infliximab (0.29 [0.15-0.56], p=0.0003), combination of infliximab and thiopurine therapy (0.34 [0.17-0.66], p=0.0016), thiopurine monotherapy (0.46 [0.24-0.87], p=0.017) and tofacitinib (0.23 [0.10-0.56], p=0.0013). Ustekinumab and vedolizumab were not associated with reduced antibody responses against A/H3N2 or A/H1N1. Vaccination in the previous year was associated with higher antibody responses to A/H3N2. Vaccine-induced anti-SARS-CoV-2 antibody concentration weakly correlated with antibodies against H3N2 (r=0.27; p=0.0004) and H1N1 (r=0.33; p<0.0001).Conclusions:Vaccination in both the 2020-2021 and 2021-2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021-2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to Influenza/A, similar to COVID-19 vaccine-induced antibody responses. Funding:Financial support was
AU - Liu,Z
AU - Alexander,JL
AU - Eng,KY
AU - Ibraheim,H
AU - Anandabaskaran,S
AU - Saifuddin,A
AU - Constable,L
AU - Seoane,RC
AU - Bewshea,C
AU - Nice,R
AU - D'Mello,A
AU - Jones,GR
AU - Balarajah,S
AU - Fiorentino,F
AU - Sebastian,S
AU - Irving,PM
AU - Hicks,LC
AU - Williams,HRT
AU - Kent,AJ
AU - Linger,R
AU - Parkes,M
AU - Kok,K
AU - Patel,KV
AU - Teare,JP
AU - Altmann,DM
AU - Boyton,RJ
AU - Hart,AL
AU - Lees,CW
AU - Goodhand,JR
AU - Kennedy,NA
AU - Pollock,KM
AU - Ahmad,T
AU - Powell,N
AU - VIP,study investigators
DO - ecco-jcc/jjad182
EP - 569
PY - 2024///
SN - 1873-9946
SP - 560
TI - Antibody responses to influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib
T2 - Journal of Crohn's and Colitis
UR - http://dx.doi.org/10.1093/ecco-jcc/jjad182
UR - https://academic.oup.com/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjad182/7371438
VL - 18
ER -